Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

2.440 -0.040 (-1.61%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
SciSparc Shares Are Soaring Monday: What's Going On? ↗
SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic... 
Via Benzinga
Topics Intellectual Property
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
From SciSparc Ltd
Via GlobeNewswire
News headline image
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet ↗
 
Via Benzinga
News headline image
S&P Jumps 1%; Regional Health Properties Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? ↗
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial. 
Via Benzinga
News headline image
US Stocks Open Higher; Dow Jumps Over 200 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
News headline image
S&P 500 Edges Lower, SciSparc Shares Surge ↗
 
Via Benzinga
Topics Stocks
News headline image
Dow Gains 50 Points, SEALSQ Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment ↗
SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors... 
Via Benzinga
News headline image
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
News headline image
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome ↗
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. 
Via Benzinga
News headline image
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy ↗
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.